1801 — Innovent Biologics Income Statement
0.000.00%
Last trade - 00:00- HK$148.36bn
- HK$130.90bn
- CNY13.04bn
Annual income statement for Innovent Biologics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4,270 | 4,556 | 6,206 | 9,422 | 13,042 |
| Cost of Revenue | |||||
| Gross Profit | 3,764 | 3,625 | 5,070 | 8,065 | 11,286 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 6,849 | 6,625 | 7,252 | 9,392 | 12,026 |
| Operating Profit | -2,579 | -2,069 | -1,046 | 30 | 1,015 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -2,642 | -2,170 | -1,144 | -78.6 | 839 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2,729 | -2,179 | -1,028 | -94.6 | 814 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2,729 | -2,179 | -1,028 | -94.6 | 814 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2,729 | -2,179 | -1,028 | -94.6 | 814 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.87 | -1.46 | -0.611 | 0.204 | 0.468 |